Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial
ConclusionSpironolactone does not reduce the risk of new-onset AF or AF recurrence in patients with HFpEF. This is in contrast to results in cohorts of patients with HF and a reduced ejection fraction.Clinical trial registrationClinicalTrials.gov identifier no. NCT00094302 (TOPCAT).
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Failure | Spironolactone